therapeutics
7 articles about therapeutics in AI news
OpenAI Launches GPT-Rosalind for Drug Discovery, GPT-5.4-Cyber for Security
OpenAI launched GPT-Rosalind, a life sciences model performing above the 95th percentile of human experts on novel biological data, and GPT-5.4-Cyber, a cybersecurity variant. These releases, alongside a major Agents SDK update, signal a pivot from general AI to specialized, high-stakes enterprise domains.
Embedding Matching Distills Genomic Models 200x, Matches mRNA-Bench Performance
A new distillation framework transfers mRNA representations from a large genomic foundation model to a specialized model 200x smaller. It uses embedding-level distillation, outperforming logit-based methods and competing with larger models on mRNA-bench.
AI-Reprogrammed Immune Cells Cure 3 Autoimmune Diseases in First Human Case
For the first time, a patient with three autoimmune diseases is in complete remission after doctors used AI to reprogram her own immune cells. This follows over a decade of requiring daily blood transfusions.
DeepMind's AlphaGenome AI Decodes Non-Coding DNA for CRISPR Targeting
Demis Hassabis states that while CRISPR can edit DNA, finding the right target is hard. DeepMind's AlphaGenome AI is analyzing the non-coding genome to predict mutation effects and guide precise CRISPR interventions.
AI Firms Target Biotech for High-Impact, High-Margin Applications
A trend analysis notes AI companies are shifting focus to biotech, where accurate prediction models can be monetized through drug discovery and synthetic biology, creating a new competitive frontier.
Eli Lilly Signs $2.75B AI Drug Discovery Deal with Insilico Medicine
Eli Lilly has entered a $2.75 billion licensing pact with Insilico Medicine for multiple AI-discovered drug programs. The deal includes an upfront payment, milestones, and royalties, marking a major validation for AI-driven pharmaceutical R&D.
From Bota to Enhe: The Dawn of Physical AI in Biomanufacturing
Bota Bio has rebranded as Enhe Technology and launched SAION AI, a pioneering Physical AI platform for biomanufacturing. The platform claims state-of-the-art performance across four key life science AI benchmarks, signaling a major shift in how biology is engineered.